CSO Rob Roscow: Transforming Research From Mydecine’s 3 Pillars Into Repeatable Medicine

How do you take a product of nature, recognize its medical potential and turn that into a medicine that’s reliable in clinical practices? That is a question Mydecine Innovations Chief Science Officer Rob Roscow contemplates every single day as he drives towards fulfilling the objectives of Mydecine’s three main operational pillars: IP/R&D, Clinical Trials and Technology.

An experienced research head, Mr. Roscow has been in this position before. Prior to joining Mydecine Innovations last May, he served as Director of Research at Ebbu, a multi-platform cannabinoid research and technology firm based in Colorado. He was tasked with activities such as operating the world’s first cannabis genomic editing facility, focusing on cannabinoid yield enhancements, filing patents, and developing a cannabis tissue culture lab.

Ebbu’s subsequent $429 million acquisition by Canopy Growth provided the segue for Mr. Roscow to focus his attention on the transformational medical mushroom space by co-founding Mydecine Group.

Among Mr. Roscow’s primary tasks will be to integrate Mydecine’s industry-leading MindLeap Health platform across in assisted-therapy apparatus. The base technology has many benefits by allowing users to track their mood and habits pertaining to mental health over time. It also allows user to interact with a catalog of activity with their therapist to achieve optimal outcomes.

Telemedicine apps have become an integral part of today’s post-COVID landscape, with Mydecine CEO Josh Bartch recently estimating that: “Seven-tenths or eight-tenths of the equation are one-on-one psychotherapy meetings between psychotherapists and patients with no substances taken at all.” The company views MindLeap as a critical platform to properly integrate and scale with the majority pf patient interactions conducted away from a physical office.

According to Grand View Research, the global telemedicine market size was estimated at USD 55.9 billion in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 22.4% from 2021 to 2028.

In the embedded interview, Rob Roscow goes into granular detail on how Mydecine is working to unlock the potential of its mycology research.

You might also like

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More